[go: up one dir, main page]

AR066669A1 - Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. - Google Patents

Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.

Info

Publication number
AR066669A1
AR066669A1 ARP080102160A AR066669A1 AR 066669 A1 AR066669 A1 AR 066669A1 AR P080102160 A ARP080102160 A AR P080102160A AR 066669 A1 AR066669 A1 AR 066669A1
Authority
AR
Argentina
Prior art keywords
alkyl
branched
linear
aryl
heteroaryl
Prior art date
Application number
Other languages
English (en)
Inventor
Tina Morwick
Peter Allen Nemoto
Lombaer Stephane De
Hidermori Takahashi
Xin Guo
Kevi Chungeng Qian
Ashita Abeywardane
Chuck Chui Man
Michael Jose Emmanuel
Steven John Taylor
Ho Yi Chungeng Qian
Ming-Hong Hao
Brian Nicholas Cook
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR066669A1 publication Critical patent/AR066669A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) en la que: A es alquilo C1-8 lineal o ramificado, alquenilo C2-8 lineal o ramificado, (CH2)m-aril-(CH2)m, (CH2)m-cicloalquil C3-8-(CH2)m o (CH2)m-cicloalquenil C3-8-(CH2)m,cada uno de ellos opcionalmente interrumpido en cada caso posible con uno o más -O-, -S-, -SO, SO2- o -NRa-, y A está sustituido con R1 y además opcionalmente sustituido con 1 a 5 sustituyentes elegidos independientemente en cada caso posible entrealquilo C1-5 lineal o ramificado, alquenilo C2-5 lineal o ramificado, cicloalquilo C3-7, cicloalquenilo C3-7, alcoxi C1-4, alcoxicarbonilo C1-4, carboxilo, alquil C1-4sulfonilo, hidroxilo, halogeno, haloalquilo C1-6, triflurometilsulfonilo,trifluorometoxi, difluorometoxi, ciano, heterocicloalquilo, arilo, heteroarilo y carboxamido o sulfonamido, donde el átomo de nitrogeno de dicha carboxamida o sulfonamida está opcional e independientemente mono o disustituido con alquilo C1-3 linealo ramificado, o el átomo de nitrogeno de dicha carboxamida o sulfonamida es parte de un anillo pirrolidinilo, piperidinilo, morfolinilo o piperazinilo; R1 es -C(O)-R4, -C(O)-N(R5)-SO2R6 o -C(O)-NR5R7, donde R4 se elige entre hidroxilo, alcoxi C1-4 yariloxi; R5 se elige entre hidrogeno o alquilo C1-3; R6 se elige entre arilo y heteroarilo; o R6 se elige entre alquilo C1-6 lineal o ramificado, amino y cicloalquilo C3-6, cada uno de ellos opcional e independientemente sustituido con 1-5sustituyentes elegidos entre alquilo C1-5, alcoxi C1-4, halogeno, ciano, arilo y heteroarilo; R7 se elige entre hidrogeno, ciano, arilo y heteroarilo; o R7 se elige entre alquilo C1-6 lineal o ramificado y cicloalquilo C3-C6, cada uno de ellosopcional e independientemente sustituido con 1-5 sustituyentes elegidos entre alquilo C1-5, alcoxi C1-4, halogeno, ciano, arilo y heteroarilo; o R1 es -SO2R8 o -SO2-NH-C(O)R9, donde R8 se elige entre hidroxilo, amino, alcoxi C1-3, ariloxi,trifluorometilo, alquilamino C1-3, dialquilamino C1-3, 1-pirrolidino, 1-piperidino y 1-morfolino; R9 se elige entre arilo y heteroarilo; o R9 se elige entre alquilo C1-6 lineal o ramificado y cicloalquilo C3-6, cada uno de ellos opcional eindependientemente sustituido con 1-5 sustituyentes elegidos entre alquilo C1-5, alcoxi C1-4, halogeno, ciano, arilo y heteroarilo; o R1 es -NH-C(O)-N(R5)-SO2R10 donde R10 se elige entre alquilo C1-5, arilo y heteroarilo; o R1 es tetrazolilo odioxotiadiazolidinona; R2 es arilo o heteroarilo; R3 es carboxilo, halogeno, ciano, alquilo C1-3, -NHR11, pirrolidino, piperidino, morfolino, -C(O)-R12 o C(O)-NR13R14; R11 se elige entre hidrogeno, carboxamido, alquilo C1-4, alcoxicarbonilo C1-4,arilo, bencilo y heteroarilo; R12 es alcoxi C1-4; R13 es heteroarilo, heterociclilo o alquilo C1-4, cada uno de ellos opcionalmente sustituido con 1-3 sustituyentes elegidos entre arilo, heteroarilo, heterociclilo, hidroxi, alcoxi C1-3, oxo,tioalquilo y dimetilamino; R14 se elige entre hidrogeno y alquilo C1-4 opcionalmente sustituido con 1-2 grupos hidroxilo; o R13 y R14 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico de 5-6 miembros opcionalmentesustituido con 1-3 sustituyentes elegidos entre halogeno, alquilo C1-3, alcoxi C1-3, hidroxilo, hidroximetilo, carboxamido, N-acetil-N-metilamino y ciano; n = 0-3 y m = 0-6; donde todos los grupos arilo o heteroarilo están opcionalmente sustituidoscon 1-5 sustituyentes elegidos entre halogeno, hidroxilo, ciano, alquilo C1-6 lineal o ramificado, alcoxi C1-6 lineal o ramificado, alquiltio C1-6 lineal o ramificado, alquilsulfonilo C1-6 lineal o ramificado, fenilsulfonilo, acilo C1-6 lineal oramificado, acilamino C1-6 lineal o ramificado, polihalometilo, polihalometoxi, fenilo, oxo, -COORa, -CON(Rc)Ra, SO2N(Rc)Ra, -N(Rc)Ra y fenoxi opcionalmente sustituido con uno o más halogenos; cada uno de Ra y Rc es independientemente alquilo C1-3 ohidrogeno; con la condicion de que cuando A es alquilo C1-3 lineal o ramificado, y R1 es -C(O)-OH, -C(O)-NH2 o -C(O)OC2CH3, y R3 es alquilo inferior, alcoxi inferior o halogeno, y n = 0-2, entonces R2 no es naftilo sin sustituir, tienilo sinsustituir, furanilo sin sustituir o fenilo con 0-2 sustituyentes seleccionados entre halogeno, trifluorometilo, alquilo inferior o alcoxi inferior; o una sal farmacéuticamente aceptable del mismo.
ARP080102160 2007-05-22 2008-05-21 Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. AR066669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93945207P 2007-05-22 2007-05-22

Publications (1)

Publication Number Publication Date
AR066669A1 true AR066669A1 (es) 2009-09-02

Family

ID=39619253

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102160 AR066669A1 (es) 2007-05-22 2008-05-21 Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.

Country Status (8)

Country Link
US (1) US9150556B2 (es)
EP (1) EP2152674B1 (es)
JP (1) JP5268120B2 (es)
AR (1) AR066669A1 (es)
AT (1) ATE518840T1 (es)
CA (1) CA2687821C (es)
TW (1) TW200901982A (es)
WO (1) WO2008147697A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152674B1 (en) 2007-05-22 2011-08-03 Boehringer Ingelheim International GmbH Benzimidazolone chymase inhibitors
US9062056B2 (en) * 2008-09-09 2015-06-23 Boehringer Ingelheim International Gmbh Aza-benzimidazolone Chymase inhibitors
WO2010088195A1 (en) * 2009-01-30 2010-08-05 Boehringer Ingelheim International Gmbh Azaquinazolinediones useful as chymase inhibitors
CN102448927A (zh) * 2009-04-01 2012-05-09 力奇制药公司 活性亚甲基基团的二甲基化的方法
US8846660B2 (en) 2009-12-25 2014-09-30 Daiichi Sankyo Company, Ltd. Seven-membered ring compound and pharmaceutical use therefor
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
MY170941A (en) 2011-04-08 2019-09-19 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
IN2014MN00862A (es) 2011-11-09 2015-04-17 Janssen R & D Ireland
JP2015519387A (ja) * 2012-06-15 2015-07-09 ヤンセン・アールアンドデイ・アイルランド Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
US20150111868A1 (en) 2012-06-15 2015-04-23 Jansen R&D Ireland Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
AU2013288600B2 (en) 2012-07-13 2017-06-29 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
EP2906553B1 (en) 2012-10-10 2019-06-26 Idorsia Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero)aryl)-pyrrolidin-1-yl]-methanone derivatives
MX365114B (es) 2012-10-10 2019-05-23 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades.
MY171115A (en) 2012-11-16 2019-09-26 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
ES2625456T3 (es) 2013-03-29 2017-07-19 Janssen Sciences Ireland Uc Desazapurinonas macrocíclicas para el tratamiento de infecciones víricas
JP6377139B2 (ja) 2013-05-24 2018-08-22 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体
PL3030563T3 (pl) 2013-06-27 2018-01-31 Janssen Sciences Ireland Uc Pochodne pirolo [3,2-d] pirymidyny do leczenia zakażeń wirusowych i innych chorób
EP3027624B1 (en) 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
CN107405319A (zh) * 2014-11-03 2017-11-28 希罗姆波尔蒂克斯有限责任公司 抗纤维蛋白溶解化合物
SG11201811448RA (en) 2016-07-01 2019-01-30 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines for the treatment of viral infections
EA038646B1 (ru) 2016-09-29 2021-09-28 Янссен Сайенсиз Айрлэнд Анлимитед Компани Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
EP3338780A1 (de) * 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CN111615513A (zh) 2018-01-19 2020-09-01 爱杜西亚药品有限公司 C5a受体调节剂
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
WO2021250180A1 (en) 2020-06-11 2021-12-16 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same
TW202506649A (zh) * 2023-03-31 2025-02-16 南韓商Ｌｇ化學股份有限公司 作為自分泌運動因子（ａｕｔｏｔａｘｉｎ）抑制劑的新穎苯並咪唑酮衍生化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH599177A5 (es) * 1974-11-29 1978-05-12 Ciba Geigy Ag
US4209527A (en) * 1979-05-16 1980-06-24 Pfizer Inc. Benzimidazolone derivatives
DE3042481A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln (omega)-(2-oxo-benzazolinyl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
AU734615B2 (en) * 1996-12-06 2001-06-21 Cortech, Inc. Serine protease inhibitors
US6248770B1 (en) 1998-07-09 2001-06-19 Boehringer Ingelheim Pharma Kg Benzimidazoles having antithrombotic activity
US6420410B1 (en) * 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
JP2003505376A (ja) * 1999-07-21 2003-02-12 藤沢薬品工業株式会社 ベンズイミダゾロン誘導体およびそのホスホジエステラーゼ阻害剤としての用途
JP4059671B2 (ja) * 2000-01-17 2008-03-12 帝人株式会社 ベンズイミダゾール誘導体
US6506738B1 (en) 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
CA2519475A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
US20080070867A1 (en) * 2005-01-19 2008-03-20 Metabasis Therapeutics, Inc. 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases
JP2009515973A (ja) 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロラクタム三環式ｃｇｒｐ受容体アンタゴニスト
WO2007061696A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam bicyclic cgrp receptor antagonists
WO2007061694A2 (en) * 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin tricyclic cgrp receptor antagonists
EP2152674B1 (en) 2007-05-22 2011-08-03 Boehringer Ingelheim International GmbH Benzimidazolone chymase inhibitors

Also Published As

Publication number Publication date
TW200901982A (en) 2009-01-16
ATE518840T1 (de) 2011-08-15
US9150556B2 (en) 2015-10-06
JP2010528024A (ja) 2010-08-19
EP2152674B1 (en) 2011-08-03
US20100240702A1 (en) 2010-09-23
CA2687821C (en) 2015-04-14
EP2152674A1 (en) 2010-02-17
WO2008147697A1 (en) 2008-12-04
JP5268120B2 (ja) 2013-08-21
CA2687821A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR127309A2 (es) Derivados de piridazinona
AR046394A1 (es) Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
PE20210040A1 (es) Moduladores de la via de estres integrada
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR077434A1 (es) Compuestos para la reduccion de produccion de beta - amiloide
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
ECSP10010473A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización
AR054320A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
PE20141405A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR048042A1 (es) Inhibidores no nucleosidos de transcriptasa inversa y composiciones farmaceuticas
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR048974A1 (es) Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure